Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
IONIS PHARMACEUTICALS INC director Joan E. Herman received new equity awards as part of non-employee director compensation. On July 1, 2026, Herman was granted 2,301 Restricted Stock Units, each representing a right to receive one share of Ionis common stock or its cash equivalent, subject to vesting.
On the same date, Herman was also granted options on 5,369 shares of common stock at an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, consistent with the company’s non-employee director compensation policy that caps 2026 equity compensation at $400,000 based on grant-date fair value.
Ionis Pharmaceuticals director Joseph Klein III reported multiple equity transactions in company stock. On July 1, 2026, he exercised options covering 11,518 shares of common stock at an exercise price of $39.94 per share and sold 11,518 shares in open-market transactions at weighted average prices around $79 per share pursuant to a Rule 10b5-1 trading plan adopted on November 25, 2025. He also received grants of 2,301 restricted stock units and 5,369 non-qualified stock options with a strike price of $79.19 per share under the company’s non-employee director compensation programs. A separate filing entry notes 200 shares held indirectly by his son, which he disclaims as beneficially owned.
IONIS PHARMACEUTICALS INC director equity awards: Non-employee director Michael R. Hayden received a grant of 2,301 Restricted Stock Units and 5,369 non-qualified stock options on July 1, 2026 as compensation. After the RSU grant, he holds 12,198 common-share equivalents directly.
The options have a $79.19 exercise price and both awards vest 100% on the earlier of the first anniversary of grant or the next annual stockholder meeting. Under the company’s non-employee director compensation policy, the 2026 equity awards were adjusted so Hayden’s total annual equity compensation does not exceed $400,000 based on grant date fair value.
Ionis Pharmaceuticals director Allene M. Diaz received equity awards as part of non-employee director compensation. On July 1, 2026, Diaz was granted 2,301 Restricted Stock Units and a Non-Qualified Stock Option for 5,369 shares of common stock at an exercise price of $79.19 per share.
The RSUs and options were granted under the company’s Amended and Restated 2002 Non-Employee Directors' Stock Option Plan and were adjusted so total 2026 equity compensation does not exceed $400,000 in grant date fair value under FASB Topic ASC 718. Both awards vest 100% on the earlier of the first anniversary of grant or the next annual stockholder meeting.
IONIS PHARMACEUTICALS INC director Spencer R. Berthelsen received equity awards as non-cash compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units, each representing one share of Ionis common stock or its cash equivalent. These RSUs vest 100% on the earlier of the first anniversary of grant or the next regularly scheduled annual stockholder meeting, and will be delivered on the following July 15.
He was also granted 5,369 non-qualified stock options with an exercise price of $79.19 per share under the Amended and Restated 2002 Non-Employee Directors' Stock Option Plan, vesting 100% on the same schedule and not exercisable as of the grant date. Following the RSU grant, he holds 7,521 RSUs. The company states that, under its Non-Employee Director Compensation Policy, these grants were adjusted so that his 2026 annual equity compensation does not exceed $400,000 based on grant date fair value under FASB Topic ASC 718.
Ionis Pharmaceuticals EVP and Chief Business Officer Joseph Baroldi reported indirect spouse transactions in Ionis common stock. On June 26, 2026, Baroldi’s spouse exercised options for a total of 5,635 shares of common stock at exercise prices of $32.60 and $56.78 per share and then sold 5,635 shares in an open-market transaction at a weighted average price of $80.1595 per share under a pre-arranged Rule 10b5-1 Trading Plan. Following these transactions, Baroldi holds 48,522 shares directly, and his spouse holds 4,669 shares indirectly attributable to him.
IONIS PHARMACEUTICALS INC executive Patrick R. O’Neil sold 3,069 shares of common stock in an open-market transaction. The shares were sold at $80.00 per share, and he now directly holds 61,470 shares following the sale.
The transaction was executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which typically means it was scheduled in advance rather than timed discretionarily.
Ionis Pharmaceuticals executive Eugene Schneider reported an exercise-and-sale transaction in company stock. On June 26, 2026, he exercised options to acquire 26,000 shares of common stock at $60.89 per share, then sold 26,000 shares in open-market trades at a weighted-average price of $81.046 per share.
The sales were executed under a pre-arranged Rule 10b5-1 Trading Plan adopted on November 19, 2025. After these transactions, Schneider directly held 77,114 shares of Ionis common stock.
Ionis Pharmaceuticals CEO Brett P. Monia reported a series of option exercises paired with open-market sales of common stock. Over June 24–26, 2026, he exercised options covering 85,637 shares and sold the same number of shares in the market, a net disposition.
Sales included 50,000 shares at a weighted average price of $80.59, 21,072 shares at $78.49, and 14,565 shares at $78.4128. The filing states these sales were made pursuant to a Rule 10b5-1 Trading Plan. After the transactions, he directly holds 245,571 shares of common stock and 99,872 non-qualified stock options.